Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Numab Therapeutics AG

Numab Therapeutics Announces Leadership Transition and Appoints Angehrn Pavik as Chief Executive Officer
From Numab Therapeutics AG
Via GlobeNewswire
Numab Therapeutics Announces Series C Extension to CHF 180 Million, Completing Oversubscribed CHF 50 Million Financing
From Numab Therapeutics AG
Via GlobeNewswire
Numab Therapeutics Announces Initiation of Phase 1 Clinical Study of NM32 Program in Patients with Solid Tumors
From Numab Therapeutics AG
Via GlobeNewswire
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis
From Numab Therapeutics AG
Via GlobeNewswire
Tickers JNJ
Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer
From Numab Therapeutics AG
Via GlobeNewswire
Numab Therapeutics Announces First Patient Dosed in Phase 1 Multiple Ascending Dose (MAD) Study of NM26 for Moderate to Severe Atopic Dermatitis
From Numab Therapeutics AG
Via Business Wire
Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program
From Numab Therapeutics AG
Via Business Wire
Numab Therapeutics and Ono Pharmaceutical Enter Development and License Agreement for Multispecific Antibody Candidate Involving Novel Immuno-Oncology Target
From Numab Therapeutics AG
Via Business Wire
Numab and 3SBio’s Sunshine Guojian Expand Partnership to Develop Novel T Cell Engager NM28
From Numab Therapeutics AG
Via Business Wire
Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing
From Numab Therapeutics AG
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.